SCHEMBL14770587

SCHEMBL14770587

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4ccc(Cl)cc4)cc3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 1/20 0.46
MAOB P27338 8/20 0.43
FFAR1 O14842 1/20 0.42
MAOA P21397 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
ACHE P22303 1/20 0.41
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CNR2 P34972 1/20 0.39
TEC P42680 1/20 0.38
APP P05067 1/20 0.38
DHFR P00374 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770573 0.91 MEN1 (0.46) MEN1KMT2AHTTMAOBFFAR1
SCHEMBL14770571 0.90 KMT2A (0.46) MEN1KMT2AHTTMAOBFFAR1
SCHEMBL14770568 0.89 MEN1 (0.47) MEN1KMT2AHTTMAOBSMN1; SMN2
SCHEMBL12065317 0.88 FFAR1 (0.45) MEN1KMT2AHTTMAOBFFAR1
SCHEMBL14770580 0.83 FFAR1 (0.46) MEN1KMT2AHTTMAOBFFAR1
SCHEMBL14770595 0.83 MAOA (0.44) MEN1KMT2AHTTMAOASMN1; SMN2
SCHEMBL14770535 0.82 MEN1 (0.53) MEN1KMT2AHTTSMN1; SMN2NPC1
SCHEMBL14770590 0.82 HTT (0.43) MEN1KMT2AHTTMAOBFFAR1
SCHEMBL14770526 0.81 CACNA1C (0.48) MEN1KMT2AHTTMAOBSMN1; SMN2
SCHEMBL14770579 0.80 CYP1A2 (0.46) MEN1KMT2AHTTMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885KMT2A 4545/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.